Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for vTv Therapeutics (VTVT) over the last 10 years, with Q4 2024 value amounting to 28776.47%.

  • vTv Therapeutics' EBITDA Margin changed N/A to 28776.47% in Q4 2024 from the same period last year, while for Sep 2025 it was 175382.35%, marking a year-over-year decrease of 1729828500.0%. This contributed to the annual value of 2377.58% for FY2024, which is N/A changed from last year.
  • Latest data reveals that vTv Therapeutics reported EBITDA Margin of 28776.47% as of Q4 2024.
  • Over the past 5 years, vTv Therapeutics' EBITDA Margin peaked at 28.6% during Q4 2020, and registered a low of 123433.33% during Q4 2021.
  • In the last 4 years, vTv Therapeutics' EBITDA Margin had a median value of 34616.81% in 2024 and averaged 37016.52%.
  • As far as peak fluctuations go, vTv Therapeutics' EBITDA Margin skyrocketed by 912857400bps in 2020, and later crashed by -1234619300bps in 2021.
  • Over the past 4 years, vTv Therapeutics' EBITDA Margin (Quarter) stood at 28.6% in 2020, then tumbled by -431712bps to 123433.33% in 2021, then skyrocketed by 43bps to 70477.78% in 2022, then skyrocketed by 59bps to 28776.47% in 2024.
  • Its EBITDA Margin stands at 28776.47% for Q4 2024, versus 562.7% for Q1 2024 and 70477.78% for Q4 2022.